Phase:III, II
Principal Investigator(s):Lynn Paxton, MD
Objective:Tested whether daily TDF/FTC (Truvada) was safe for HIV-negative sexually-active young adults in Botswana and whether it reduced risk of HIV infection.Key results: 62% Reduction in HIV infection rate on Daily oral TDF/FTC among heterosexual males and females in Botswana, underpowered for sex differences. Last updated August 10, 2022